Vascular Access News

Use of a risk score while monitoring the patency of a hemodialysis vascular access may help predict the development of stenosis and provide an objective measure for risk stratification, researchers concluded in a recently published study.

Among patients with kidney failure who successfully used a permanent access for hemodialysis, the incidence of patency loss was higher with arteriovenous graft use compared with arteriovenous fistula, according to data in Kidney Medicine.

ORLANDO — In this video from ASN Kidney Week, Krithika Rajagopalan, PhD, MPH, discusses the importance of identifying catheter-related bloodstream infections in patients using central venous catheters.

Patients using hemodialysis reported less pain when listening to music during the cannulation procedure, according to data published in the Clinical Journal of the American Society of Nephrology.

Nephrologists have several options when it comes to new vascular access devices and technologies, according to a presentation at the Innovations in Dialysis: Expediting Advances Symposium.

W. L. Gore & Associates Inc. is acquiring InnAVasc Medical Inc., a medical technology company focused on developing vascular access grafts for patients with end-stage renal disease, according to a press release.

Interviews revealed earlier decisions about kidney replacement therapies impact how and when patients, caregivers and clinicians make vascular access decisions.

Xeltis announced the clinical trial of the restorative hemodialysis access graft, aXess, showed promising early puncturing, patency and safety data, according to a press release.

Arrow International issued a recall of its percutaneous thrombolytic device due to risk for tip damage during use and subsequent detachment from the basket.

Xeltis, a Swiss-Dutch medical device company, reported that it implanted patients with kidney failure who required dialysis with aXess, the first restorative synthetic hemodialysis access graft.